Recent News

• 03.31.2026 - Paysign is a Sponsor at the Pharmaceutical Compliance Congress 2026, McLean, VA
• 03.24.2026 - Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion
• 03.23.2026 - Paysign to Attend Asembia Specialty Pharmacy Summit, April 26-30, 2026
• 03.13.2026 - Reshaping Patient Affordability: The Power of Expertise and Agility
• 02.26.2026 - Paysign is Attending the Gene Therapy Development Summit, Boston, MA
• 02.24.2026 - Paysign to Host Fourth Quarter and Full Year 2025 Earnings Call
• 02.18.2026 - Paysign is a Sponsor at ACCESS USA 2026, March 17-19, Philadelphia, PA
• 01.21.2026 - Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
• 01.07.2026 - Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions
• 11.13.2025 - Paysign, Inc. to Present at the 17th Annual Southwest IDEAS Investor Conference

Recent Filings

• 03.26.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.26.2026 - DEF 14A Other definitive proxy statements
• 03.25.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.24.2026 - EX-99.1 EX-99.1
• 03.24.2026 - 8-K Current report
• 03.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 8-K Current report